Core Peptides AI Market Strategy Report - Peptide Suppliers

Answer Capsule

Core Peptides holds the second-strongest recommendation position in the peptide suppliers category for September 2026, with 15.14% valid recommendation coverage across 350 qualified AI observations. The brand appears in 26.57% of answers but converts that presence into a valid recommendation less often, and it ranks first in only 1.71% of observations. Core Peptides declined 13.0 percentage points from July 2026, though it recovered 1.9 points from August, suggesting the sharpest drop may have stabilized. The clearest opportunity sits in converting its existing presence into top-three and rank-one placements, where AminoVault currently outperforms it on first-position rate.

Who This Report Is For

This report is for Core Peptides leadership, category marketers, and commercial teams evaluating how the brand is positioned when buyers ask AI systems for a peptide supplier recommendation.

Report Card

Executive Summary

Questions This Section Answers

• Where does Core Peptides rank in the peptide suppliers category by valid recommendation coverage?
• Why is Core Peptides named often but not consistently chosen as a recommendation?
• What do the July-to-September coverage movements suggest about whether the decline has stabilized?

Core Peptides enters September 2026 as the second-ranked brand in the peptide suppliers category by valid recommendation coverage, at 15.14%. The benchmark shows the brand present in 26.57% of qualified observations, which places it third in raw mention presence behind Phoenix Pharmaceuticals at 59.7% and Biotech Peptides at 27.1%. The gap between presence and recommendation is the central story: Core Peptides is named often but is not consistently chosen.

The brand's recommendation coverage declined 13.0 percentage points across the three-month series, from 28.1% in July 2026 to 15.14% in September 2026. The sharpest movement occurred between July and August, when coverage fell 14.9 points to 13.2%. Between August and September, Core Peptides recovered 1.9 points, a change within normal month-to-month variation. The observed data suggests the July-to-August decline may have stabilized rather than continued.

Core Peptides holds 53 valid recommendations out of 350 September observations, second only to Phoenix Pharmaceuticals at 65. Its top-three rate stands at 8.57%, and its rank-one rate is 1.71%, with 6 rank-one placements across the month. The analysis found that Core Peptides converts presence into a top-three recommendation less efficiently than its coverage level would suggest.

The strongest cluster for Core Peptides is C01, Best Research Peptide Companies and Sources, which carries all 350 qualified observations in the current public series. The C02 and C03 clusters, covering supplier comparisons and pricing queries, contain zero qualified observations, meaning the benchmark cannot yet measure how Core Peptides performs when buyers compare suppliers or evaluate pricing.

The strongest platform signal for Core Peptides is Copilot, where the brand reaches 34.8% valid recommendation coverage, the highest platform-level rate in its profile. Perplexity also shows strength at 27.8% coverage. The clearest platform gap is Gemini, where Core Peptides holds only 4.4% coverage despite 24.6% raw presence, indicating the brand is mentioned but rarely recommended on that surface.

The benchmark shows Core Peptides with a net sentiment score of 0.7527, reflecting 70 positive mentions, 23 neutral mentions, and zero negative mentions. The framing is consistently positive or neutral, with no cautionary language detected in the qualified observation set.

What Core Peptides Is Winning

Questions This Section Answers

• Which platforms deliver Core Peptides's strongest recommendation coverage?
• How does Core Peptides's sentiment profile compare with the rest of the category?

Core Peptides holds the second-highest valid recommendation count in the category at 53, behind only Phoenix Pharmaceuticals at 65. This places the brand ahead of Biotech Peptides at 46 and AminoVault at 39, despite AminoVault's higher rank-one rate.

The brand's strongest platform is Copilot, where it achieves 34.8% valid recommendation coverage across 46 platform observations. This is the highest platform-level coverage rate in the Core Peptides profile and indicates that Copilot surfaces are recommending the brand at a meaningfully higher rate than the category average.

Perplexity represents a second area of strength, with Core Peptides reaching 27.8% valid recommendation coverage and a 22.2% top-three rate across 18 platform observations. The brand's average recommended rank on Perplexity is 3.2, suggesting it appears in recommendation positions but not consistently at the top.

Core Peptides shows zero negative mentions across all 350 qualified observations. The absence of cautionary or negative framing is a meaningful baseline, as it means the brand's challenge is recommendation conversion rather than reputation repair.

The brand's net sentiment score of 0.7527 is the third-highest in the category, behind Blue Sky Peptide at 0.9200 and AminoVault at 0.8657. This indicates that when Core Peptides is mentioned, the framing is predominantly positive.

Where Core Peptides Has the Clearest AI Visibility Gaps

Questions This Section Answers

• Where is Core Peptides visible but under-recommended by AI systems?
• Why does Core Peptides rank first far less often than AminoVault despite higher recommendation coverage?
• Why does Gemini mention Core Peptides but rarely recommend it?

Core Peptides is visible but under-recommended relative to its presence level. The brand appears in 26.57% of qualified observations but receives a valid recommendation in only 15.14%. This 11.4-point gap between presence and recommendation is the clearest signal that the brand is being named as context rather than chosen as a recommendation.

The rank-one gap is more pronounced. Core Peptides ranks first in only 1.71% of observations, compared to AminoVault at 5.71% and Phoenix Pharmaceuticals at 3.14%. Despite holding higher valid recommendation coverage than AminoVault, Core Peptides is significantly less likely to be the single top recommendation. The observed data suggests that when AI systems recommend Core Peptides, they typically place it second or third rather than first.

Gemini represents the clearest platform-level gap. Core Peptides holds 24.6% raw mention presence on Gemini but only 4.4% valid recommendation coverage. The brand is being mentioned on Gemini at a rate comparable to its category presence, but those mentions are not converting into recommendations. This pattern suggests the brand may be appearing as a reference or comparison anchor rather than as a recommended option.

The C02 and C03 clusters, covering supplier comparisons and pricing queries, contain zero qualified observations in the current benchmark. This means Core Peptides cannot yet be measured on how it performs when buyers ask AI systems to compare suppliers head-to-head or evaluate pricing options. Those query types represent a significant portion of buyer decision journeys that the current public series does not capture.

Biotech Peptides, despite lower valid recommendation coverage at 13.1%, holds a higher raw mention presence rate at 27.1% and a comparable top-three rate at 7.14%. The competitive field is compressed, with the top four brands separated by fewer than 6 percentage points in coverage. Core Peptides' second-place position is not secure.

Biggest Opportunity

Questions This Section Answers

• What is the most direct path for Core Peptides to improve its recommendation-stage visibility?
• Which prompt cluster and platform gap should Core Peptides prioritize?

The clearest opportunity for Core Peptides is converting its existing presence into top-three and rank-one recommendation placements. The brand is already being mentioned in more than one in four qualified observations, but it converts that presence into a valid recommendation less than 60% of the time. The gap between presence and recommendation represents the most direct path to improving recommendation-stage visibility.

This opportunity is concentrated in the C01 cluster, where all current qualified observations sit. The prompts in this cluster include direct recommendation queries such as "best place to buy peptides online" and "What is the best peptide company to buy from?" Core Peptides is present in these answers but is not consistently positioned as a top choice. Improving the brand's recommendation placement within this cluster would directly address the rank-one gap.

The platform-level opportunity is most acute on Gemini, where Core Peptides holds 24.6% presence but only 4.4% recommendation coverage. Closing that gap would bring Gemini performance in line with the brand's Copilot and Perplexity results.

Competitive Landscape

Questions This Section Answers

• How does Core Peptides compare with competitors on top-three, rank-one, average rank, and sentiment?
• Where does Core Peptides's recommendation strength sit relative to Phoenix Pharmaceuticals, AminoVault, and Biotech Peptides?

Phoenix Pharmaceuticals holds the strongest recommendation-stage position in the peptide suppliers category, with Core Peptides, Biotech Peptides, and AminoVault forming a compressed challenger group behind it. Core Peptides ranks second by valid recommendation coverage but fourth by rank-one rate, indicating that its recommendation strength is concentrated in lower placement positions.

Average recommended rank covers rank-eligible recommendations only.

Core Peptides holds the second-highest top-three rate in the category at 8.57%, but its rank-one rate of 1.71% places it fourth, behind AminoVault, Phoenix Pharmaceuticals, and Biotech Peptides. The brand's average recommended rank of 3.38 is the highest among the top four brands, meaning that when Core Peptides is recommended, it typically appears in the third position rather than the first or second.

Prompt Evidence

Copilot / Best Research Peptide Companies and Sources Prompt: "best place to buy peptides online" Result: Core Peptides received a valid recommendation with a top-three placement, contributing to its 34.8% coverage rate on Copilot.

Gemini / Best Research Peptide Companies and Sources Prompt: "What is the best peptide company to buy from?" Result: Core Peptides was mentioned but did not receive a valid recommendation, reflecting the brand's 4.4% recommendation coverage on Gemini despite 24.6% presence.

Perplexity / Best Research Peptide Companies and Sources Prompt: "What are the best peptides to buy?" Result: Core Peptides appeared in a top-three recommendation position, contributing to its 22.2% top-three rate on Perplexity.

Google AI Overviews / Best Research Peptide Companies and Sources Prompt: "best peptide company" Result: Core Peptides received a valid recommendation with an average rank of 2.06 across AI Overviews observations, indicating consistent second-position placement.

What CiteWorks Studio Would Do Next

Phase 1: AI Market Discovery Audit Map the specific prompts where Core Peptides is mentioned but not recommended, and identify which competitors capture the recommendation when Core Peptides is displaced.

Phase 2: Recommendation Readiness Plan Prioritize the Gemini platform gap and the rank-one conversion gap, focusing on the C01 cluster prompts where Core Peptides already has presence.

Phase 3: Owned Answer Layer Buildout Develop owned content that directly addresses the recommendation criteria AI systems appear to use when selecting top peptide suppliers, with emphasis on first-position attributes.

Phase 4: Citation and Authority Layer Development Strengthen the public evidence layer that AI systems retrieve when forming recommendations, ensuring Core Peptides is associated with the attributes that drive top-three placement.

Phase 5: Monthly AI Visibility and Recommendation Tracking Track recommendation coverage, top-three rate, and rank-one rate monthly to measure whether the conversion gap is closing and whether Gemini performance improves.

Why This Matters

Core Peptides is visible in more than one in four AI answers about peptide suppliers, but it is recommended in fewer than one in six. The gap between presence and recommendation represents buyers who see the brand name but do not see it positioned as a top choice. In a category where the top four brands are separated by fewer than 6 percentage points in coverage, the difference between being mentioned and being recommended is the difference between entering the buyer shortlist and being passed over.

The benchmark shows that presence alone does not drive recommendation. Core Peptides has the third-highest raw mention presence in the category but the fourth-highest rank-one rate. The next move is targeted correction of the prompt, page, and citation layers that influence how AI systems position the brand when buyers ask for a recommendation.

Core Metrics

Sentiment Score

Questions This Section Answers

• Why can a brand with high mention volume still be overrated by raw counts?
• What does Core Peptides's mix of positive, neutral, and negative mentions reveal about how it is framed?

Sentiment Score = (positive mentions × 1 + neutral mentions × 0 + negative mentions × -1) / total mentions

For Core Peptides in September 2026: (70 × 1 + 23 × 0 + 0 × -1) / 93 = 0.7527

This score matters because unclassified mention counts are misleading. A brand with 93 mentions could appear strong, but if those mentions are neutral references or comparison anchors rather than positive recommendations, the raw count overstates the brand's position. Share of voice is a diagnostic metric, not a business KPI.

A positive recommendation, a neutral reference, a cautionary mention, and a competitor-displaced mention are not equal. Core Peptides has zero negative mentions, which is a positive baseline, but 23 of its 93 mentions are neutral. Those neutral mentions represent instances where the brand is named but not framed as a recommended choice. Counting all mentions as wins would obscure the distinction between being recommended and being referenced.

Classified sentiment is required before interpreting AI visibility. The 0.7527 score indicates that Core Peptides is predominantly framed positively when mentioned, but the score does not capture whether those positive mentions translate into recommendation placement. A brand can have high sentiment and low recommendation conversion, which is the pattern the benchmark shows for Core Peptides.

Sentiment by Platform

Methodology

1. This report is a benchmark-based analysis of Core Peptides' position in the peptide suppliers category, using data from the LLM Authority Index AI Market Discovery Index for September 2026.
2. The reporting window covers September 2026, with comparison data from July 2026 and August 2026 where available.
3. Six AI platforms were tracked: ChatGPT, Copilot, Gemini, Perplexity, Google AI Overviews, and Google AI Mode. All six produced qualified observations in September 2026.
4. The benchmark began with 530 prompt-surface observations in September 2026, representing 349 unique questions. After qualification, 350 observations formed the public denominator for all metrics.
5. The competitor universe includes seven tracked brands: Core Peptides, Phoenix Pharmaceuticals, Biotech Peptides, AminoVault, Blue Sky Peptide, Peptides Source, and Peptide Tech.
6. Three public clusters were defined: C01 (Best Research Peptide Companies and Sources), C02 (Peptide Supplier and Product Comparisons), and C03 (Research Peptide Pricing and Where to Buy). All 350 qualified observations fell into C01.
7. Stage 0 extraction retained the query, AI surface, answer, brand outcome, recommendation placement, sentiment, and citations where exposed. Source presence is evidence about the information environment and is not treated as proof of causation.
8. A mention is defined as any instance where Core Peptides appears in an AI-generated answer, regardless of recommendation status.
9. A valid recommendation is defined as an instance where Core Peptides is explicitly recommended or shortlisted, as marked by the dataset. Neutral references, comparison anchors, and listed-only mentions are not counted as valid recommendations.
10. Top-three rate measures the share of qualified observations where Core Peptides appears among the top three recommended options. Rank-one rate measures the share where Core Peptides is the single top recommendation.
11. Average recommended rank covers rank-eligible recommendations only. Core Peptides' average rank of 3.38 reflects its position when it receives valid rank credit.
12. The C02 and C03 clusters contained zero qualified observations in September 2026, meaning the benchmark cannot yet measure Core Peptides' performance on comparison or pricing queries. This is a limitation of the current public series.
13. Small counts warrant caution. Core Peptides holds 53 valid recommendations, which is sufficient for directional analysis but does not support precise month-to-month comparisons at the platform level.
14. Movement in this category is calculated against a qualified denominator that grew from 274 observations in July 2026 to 350 in September 2026. Comparisons are made between qualified sets, not raw collections.

See Where Core Peptides Stands in AI Recommendations

The LLM Authority Index tracks how often and how prominently brands appear in AI-generated answers across the major AI and search surfaces. A company-level Authority Index can show which specific prompts Core Peptides is winning, which competitors are capturing recommendations when Core Peptides is displaced, and which evidence sources are shaping those outcomes.